Biotech Values

[bellweather1]

ARRY/mcbio

No, I didn't get a chance to listen(these are, due to all the programs, often rather protracted affairs).

I think, if nothing else, the market, for the moment at least, is acknowledging a company selling for 159ml with so many shots on goal(however questionable the odds per shot), that's functioning with close to a balanced budget.

This has been the overarching investment case for Arry all along.

I just think that many lose site of it-particularly in view of what appears to be a history of underwhelming results.

But the question is what does mcbio think?

When does the current "quiet period" expire:)?

Best,

bw